FDA reauthorization bill passes Senate committee

Share this article:
 
A funding reauthorization bill that regulates the Food and Drug Administration cleared a hurdle Wednesday when a Senate committee approved it.
 
The legislation, approved by the Health, Education, Labor and Pensions Committee, reauthorizes user fees that drug and medical device industries pay to the FDA. It also adds a new fee for companies that make generic medications, specifically allowing the government to collect $299 million each year in fees from the generic drug industry for four years.
 
If the bill passes, it also would allow FDA reviewers to speed up the clearance of products for rare disease. The language also calls for developing incentives for "development of new qualified infectious disease products (QIDPs) by providing an additional five years of market exclusivity." That could be good news for nursing homes, where infectious diseases can be deadly to vulnerable seniors.
 
Congress has to send the bill to the president by Oct. 1. To read the HELP committee's bill, click here.
Share this article:

More in News

House leader urges HHS to end settlements meant to cut Medicare backlog

The Department of Health and Human Services may not have had the authority to offer providers special settlements to help clear a huge backlog of Medicare appeals, a leading Congressman said in a recent letter to the agency. Rep. Kevin Brady (R-TX) is urging HHS ...

One-fifth of caregivers take 6 months or longer to choose a senior ...

A significant number of people take six months or longer to choose a senior care or housing option for a loved one, recently released survey results showed.

CMS releases updated Minimum Data Set manual

CMS releases updated Minimum Data Set manual

The Centers for Medicare & Medicaid Services released an updated version of the Minimum Data Set 3.0 Resident Assessment Instrument manual Friday.